BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BioXcel Therapeutics, Inc. (BTAI)
Today's Latest Price: $45.70 USD
Updated Dec 4 4:00pm
Add BTAI to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BTAI Stock Price Chart Interactive Chart >
BTAI Price/Volume Stats
| Current price | $45.70 | 52-week high | $71.50 |
| Prev. close | $45.43 | 52-week low | $5.58 |
| Day low | $44.50 | Volume | 207,600 |
| Day high | $46.03 | Avg. volume | 578,324 |
| 50-day MA | $48.35 | Dividend yield | N/A |
| 200-day MA | $42.52 | Market Cap | 1.11B |
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Loading social stream, please wait...